For decades, general health and science information has served as the foundation for public understanding of medical conditions and treatment options. This broad educational context has empowered individuals to make informed decisions about their well-being, from preventive care to managing chronic diseases. Within this framework, the discussion of prescription medications has always emphasized both benefits and potential risks, fostering a balanced perspective on therapeutic interventions. As this legacy of health literacy evolves, a more focused concern has emerged regarding specific pharmaceutical exposures and their long-term consequences. In particular, the use of bisphosphonate medications like Fosamax has drawn attention due to reports linking prolonged use to rare but serious adverse events. Among these, osteonecrosis of the jaw—a condition involving bone tissue death in the jaw—has become a subject of heightened scrutiny for patients and healthcare providers alike. This pivot from general health awareness to occupational and therapeutic exposure concern is critical. For individuals in North Carolina who have taken Fosamax and subsequently developed jaw complications, understanding the legal dimensions—such as the statute of limitations for filing a claim—becomes paramount. The transition from broad health education to specific risk assessment underscores the need for timely action, as legal recourse depends on adhering to state-specific deadlines. Thus, the general health heritage now channels into a targeted inquiry: how past medication exposure may intersect with current legal rights.
Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms of ONJ after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is rare, as indicated by research showing that the incidence of atypical femoral fracture or osteonecrosis of jaw was uncommon and rare respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/).
From a medical risk perspective, patients who have taken Fosamax and developed ONJ may face significant health challenges, including pain, infection, and difficulty eating. The adequacy of warnings regarding Fosamax and ONJ is a critical consideration. The FDA-approved labeling for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the labeling also states that in placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This may raise questions about whether the warnings were sufficiently clear or timely for patients and healthcare providers. For affected patients in North Carolina, attorney-related considerations are important. The statute of limitations for filing a product liability lawsuit in North Carolina is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. Given that ONJ can develop months or even years after starting Fosamax, the timeline between exposure and documented harm is a key factor. The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This means that patients who have taken Fosamax for several years may be at higher risk, and the harm may not become apparent until after a significant period. Patients should consult with an attorney to determine the applicable statute of limitations in their specific case, as delays in diagnosis or treatment could affect the filing deadline. In summary, Fosamax is associated with a rare but serious risk of ONJ, with onset varying from days to months after starting the drug. The risk may increase with longer exposure, and known risk factors include dental procedures and other medical conditions. Patients in North Carolina who have developed ONJ after taking Fosamax should be aware of the statute of limitations and seek legal advice promptly to preserve their rights.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In North Carolina, the statute of limitations for product liability lawsuits is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. Because osteonecrosis of the jaw (ONJ) can develop months or years after starting Fosamax, it is crucial to consult an attorney promptly to determine the applicable deadline in your specific case.
Known risk factors for ONJ include invasive dental procedures (such as tooth extraction, dental implants, or boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.